Rivastigmine Hexal-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Rivastigmine Hexal-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Fortschrittliche pharmazeutische Formulierung für gezielte therapeutische Intervention.
Dosierung
Rivastigmine Hexal-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Stärke
Rivastigmine Hexal-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Packungsgröße
Rivastigmine Hexal-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Form
Rivastigmine Hexal-H-C-PSUSA-00002654-202401: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
Quelle
European Medicines Agency
Sicherheitsprofil
Kontraindikationen
Nebenwirkungen
Scanne diesen QR-Code, um schnell auf diese Seite auf deinem Mobilgerät zuzugreifen.